GLP-1 Receptor Agonist Market Size | Forecast 2023-2028

3 minutes, 47 seconds Read

IMARC Group, a leading market research company, has recently releases report titled “GLP-1 Receptor Agonist Market Report by Product (Victoza, Ozempic, Trulicity, Bydureon, Saxenda, and Others), Route of Administration (Parenteral, Oral), Application (Type 2 Diabetes Mellitus, Obesity, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Diabetes Clinics, Online Pharmacies), and Region 2023-2028.” The study provides a detailed analysis of the industry, including the global GLP-1 receptor agonist market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights

How big is the GLP-1 receptor agonist market?

The global GLP-1 receptor agonist market size reached US$ 22.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 39.0 Billion by 2028, exhibiting a growth rate (CAGR) of 9.8 % during 2023-2028.

What is a GLP-1 receptor agonist?

GLP-1 receptor agonists are a class of medications used in the management of type 2 diabetes mellitus and, in some cases, obesity. They function by mimicking the activity of the naturally occurring glucagon-like peptide-1 (GLP-1) hormone, which plays a vital role in regulating blood sugar levels and appetite. By binding to GLP-1 receptors, these drugs stimulate the release of insulin from pancreatic beta cells, thus promoting glucose uptake and lowering blood glucose levels. They are widely available in various formulations, including injectable pens and pre-filled syringes, offering patients flexible and convenient treatment options. They also inhibit the release of glucagon, a hormone that raises blood sugar levels and slows down gastric emptying, leading to decreased appetite and a sense of fullness. As a result, GLP-1 receptor agonists are gaining immense traction across the globe as they help control blood sugar, promote weight loss, and reduce the risk of cardiovascular complications in patients with type 2 diabetes.

Request for a sample copy of this report: https://www.imarcgroup.com/glp-1-receptor-agonist-market/requestsample

What are the growth prospects and trends in the GLP-1 receptor agonist industry?

The global GLP-1 receptor agonist market is primarily driven by the rising prevalence of type 2 diabetes and obesity and the increasing adoption of GLP-1 receptor agonists as an effective treatment option. Additionally, the growing focus on developing novel and long-acting GLP-1 receptor agonists with improved therapeutic efficacy and patient compliance has augmented the demand for these medications. Moreover, the escalating investments in clinical research and the exploration of GLP-1 receptor agonists for the management of cardiovascular diseases and other metabolic disorders have catalyzed market growth by expanding the potential applications of these drugs. Furthermore, various favorable reimbursement policies and the increasing healthcare expenditure in emerging economies that improve patient accessibility to GLP-1 receptor agonist therapies are contributing to market growth. Other factors, including the heightened emphasis on lifestyle modifications and non-insulin therapies, increasing awareness of the cardioprotective and weight loss benefits, and the development of convenient administration methods, are also anticipated to create a positive market outlook in coming years.

What is included in market segmentation?

The report has segmented the market into the following categories:

Breakup by Product:

  • Victoza
  • Ozempic
  • Trulicity
  • Bydureon
  • Saxenda
  • Others

Breakup by Route of Administration:

  • Parenteral
  • Oral

Breakup by Application:

  • Type 2 Diabetes Mellitus
  • Obesity
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Diabetes Clinics
  • Online Pharmacies

Breakup by Region:

  • North America (U.S. Canada)
  • Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Others)
  • Asia Pacific (China, India, Japan, South Korea, Indonesia, Australia, and Others)
  • Latin America (Brazil, Mexico)
  • Middle East Africa

Who are the key players operating in the industry?

The report covers the major market players including:

  • Amgen Inc.
  • Eli Lilly and Company
  • Hanmi Pharm Co., Ltd.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Novo Nordisk A/S
  • Paige Biomedicine (Suzhou) Co., Ltd.
  • Sanofi S.A.

Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email: [email protected]

Follow us on Twitter: @imarcglobal

Similar Posts